The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Alliance News Detail


Silence Therapeutics Issues Intellectual Property Claim In UK Court

[ 03 Jul 2017 14:57 ]

LONDON (Alliance News) - Pharmaceutical company Silence Therapeutics PLC said on Monday it has issued an intellectual property claim in the UK High Courts of Justice against Alnylam UK Ltd, Alnylam Pharmaceuticals Inc, and The Medicines Co UK Ltd.

The claim asks the court to determine whether Silence is entitled to supplementary protection certificates on several late stage Alnylam products, which include Patisiran, Fitusiran, Givosiran and Inclisiran, which were developed with partner The Medicines Co.

London-listed Silence said it could result in the extension of its European patent protection on these products.

Supplementary protection certificates are intellectual property rights which can give up to five years of exclusivity after a patent expires.

The company said it was "committed to defending its intellectual property" and to securing the appropriate value for the intellectual property, and maintained that it "will act to enforce its patent estate as necessary".

Silence Therapeutics Chief Executive Ali Mortazavi, said the company considers "potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence. As such, we consider the commencement of this process to be the next step in realising this value".

Silence said it is also "actively continuing to uphold its patent estate in other global regions", and in May said that it will be issued with a US patent to further protect its chemical modification technology.

Shares in Silence were up 1.3% to 95.50 pence on Monday.

By Maryam Cockar; maryamcockar@alliancenews.com; @MaryamCockar

Copyright 2017 Alliance News Limited. All Rights Reserved.


Silence Therapeutics Issues Intellectual Property Claim In UK Court - Alliance News

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds